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Abstract
Objective To assess the effect of reduction or
modification of dietary fat intake on total and
cardiovascular mortality and cardiovascular morbidity.
Design Systematic review.
Data sources Cochrane Library, Medline, Embase,
CAB abstracts, SIGLE, CVRCT registry, and
biographies were searched; trials known to experts
were included.
Included studies Randomised controlled trials stating
intention to reduce or modify fat or cholesterol intake
in healthy adult participants over at least six months.
Inclusion decisions, validity, and data extraction were
duplicated. Meta›analysis (random effects
methodology), meta›regression, and funnel plots were
performed.
Results 27 studies (30 902 person years of
observation) were included. Alteration of dietary fat
intake had small effects on total mortality (rate ratio
0.98; 95% confidence interval 0.86 to 1.12).
Cardiovascular mortality was reduced by 9% (0.91;
0.77 to 1.07) and cardiovascular events by 16% (0.84;
0.72 to 0.99), which was attenuated (0.86; 0.72 to 1.03)
in a sensitivity analysis that excluded a trial using oily
fish. Trials with at least two years’ follow up provided
stronger evidence of protection from cardiovascular
events (0.76; 0.65 to 0.90).
Conclusions There is a small but potentially
important reduction in cardiovascular risk with
reduction or modification of dietary fat intake, seen
particularly in trials of longer duration.
Introduction
For half a century the relation between dietary fat and
cardiovascular disease, the “diet›heart” hypothesis, has
been a central tenet of strategies for risk reduction in
individuals and populations.1 Observational studies2
and systematic reviews of clinical trials with risk factors
as end points3–7 support this relation. However,
evidence of a beneficial effect in observational studies
does not provide convincing evidence. For example,
the protective effect of â carotene in coronary heart
disease was strongly supported by observational
evidence, but large randomised controlled trials
showed no protective effects on morbidity or
mortality.8
Previous investigators have extrapolated the reduc›
tion in coronary heart disease that might be expected
from changes in blood cholesterol concentration,4 7
even though there is direct evidence from randomised
controlled trials of the effect of modification or reduc›
tion of intake of dietary fats. We therefore performed a
systematic review to assess the effect of change in
dietary fat intake, which would be expected to result in
a lowering of cholesterol concentration, on mortality
and cardiovascular morbidity, using all available
randomised clinical trials. The interventions included
any of the following: reduction in intake of total fat;
reduction in intake of saturated fat; reduction in intake
of dietary cholesterol; or a shift from saturated to
unsaturated fat.
Methods
Much of the methodology has been reported
previously.9 Briefly, we developed a search strategy to
search for nutrition based randomised controlled trials
on the Cochrane Library, Medline, Embase, CAB
abstracts, CVRCT registry (inception of database to
mid›1998), and SIGLE (January 1999). We searched
bibliographies and contacted related Cochrane Review
Groups and 60 experts (May 1999) for further trials.
There were no language restrictions.
The inclusion criteria were adequate randomisa›
tion; usual or control diet or placebo group; stated aim
of intervention was reduction or modification of intake
of dietary fat or cholesterol, unless the intervention was
exclusively omega 3 fatty acids; intervention was not
multifactorial; the intervention group were not
children, acutely ill, or pregnant; the intervention (diet
provided or supplementation) continued for at least six
months or follow up (after dietary advice) was at least
six months; and data on mortality or cardiovascular
morbidity were available.
Our primary outcomes of interest were effects of
intervention on total mortality, cardiovascular mor›
tality, combined cardiovascular events (including all
available data on cardiovascular deaths, non›fatal myo›
cardial infarction, stroke, angina, heart failure, periph›
eral vascular disease, angioplasty, and coronary artery
bypass grafting), and quality of life. Event data were
included only when they occurred during provision of
diet or supplement (when these were provided) or
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while randomisation and blinding were maintained (in
dietary advice trials).
Inclusion was assessed independently by two asses›
sors (LH, RLT) and differences were resolved by
discussion, with, if necessary, a third reviewer (RAR).
Data extracted independently in duplicate (by LH and
RLT) included type of participants, interventions, and
outcomes; characteristics of trial quality; numbers of
events; total patient years in trial; and data on potential
effect modifiers. Effect modifiers included participants’
baseline risk of cardiovascular disease, trial duration,
mode of intervention, change in intake of dietary fats,
and serum cholesterol concentration achieved.
Criteria for assessment of trial quality included
method of randomisation, physician blinding, partici›
pant blinding, and any systematic difference in care
between the intervention groups.
We used meta›analysis to explore the primary
hypothesis, which was that reduction or modification of
dietary fat intake affects mortality, cardiovascular mor›
tality, and cardiovascular events. We examined the
effects of duration of intervention, initial level of
cardiovascular risk and dietary fat intake, type of inter›
vention, and changes in intake of total, saturated,
monounsaturated, and polyunsaturated fats and blood
cholesterol concentration using subgrouping of trials
and meta›regression. We excluded trials that aimed to
alter omega 3 intake as the method of action (if any) is
probably different from any action caused by the
reduction in intake of total or saturated fat—that is,
it does not primarily lower low density lipoprotein
cholesterol.
Treatment effect was measured as a rate ratio and
meta›analysis performed as a weighted average of log
rate ratios.10 The meta›analysis used random effects
methodology11 within S›PLUS.12 Meta›analysis pools
results of individual trials, with weighting so that results
with higher precision (related to sample size)
contribute more to the combined outcome. We used
the STATA command metareg13 for random effects
meta›regression.14 Meta›regression investigates the
effect of one or more study characteristics on the size
of treatment effect, taking precision into account. A
genuine relation may be inferred (for example, if the
extent of reduction in total fat achieved by the
intervention is associated with the degree of reduction
in mortality) when a slope is significantly different from
zero. We used funnel plot asymmetry to detect any bias
in the trials retrieved.15
Results
Study characteristics
We identified 27 studies, comprising 40 distinct
intervention arms over 30 902 person years of
observation.16–42 A table with details of all 27 studies can
be found on the BMJ ’s website. Figure 1 gives a flow
chart of studies assessed and excluded at various stages
of the review. Table 1 gives details of extracted data. We
found almost no data on quality of life or levels of trans
fats. The ê statistic for inter›rater agreement on
inclusion or exclusion of potential trials was 0.61.43
Reduction or modification of dietary fat intake
The pooled rate ratio for total mortality was 0.98 (95%
confidence interval 0.86 to 1.12), which indicates little,
if any, effect (fig 2). The data on cardiovascular
mortality indicate a slight (9%) protection from modi›
fication of intake of dietary fat (0.91; 0.77 to 1.07) (fig 3)
and a 16% reduction in cardiovascular events (0.84;
0.72 to 0.99) (fig 4). A funnel plot of effect size versus
sample size did not show any evidence of bias (data not
shown).
The Oslo diet›heart trial provided some oily fish (a
source of omega 3 fatty acids) to participants in the
intervention group.33 Exclusion of the results of this
trial attenuated the rate ratios for all three main
outcomes (total mortality 1.02 (0.91 to 1.14); cardio›
vascular mortality 0.94 (0.79 to 1.11); combined
cardiovascular events 0.86 (0.72 to 1.03)).
Figure 5 shows the results of the meta›analyses,
subgroupings, and sensitivity analyses performed.
Table 2 shows the results of the meta›regressions.
Duration of follow up, initial level of cardiovascular
risk, type of intervention, and dietary fat intake at
baseline
We obtained results for specific length of time on diet,
initial level of cardiovascular risk, or mode of interven›
tion through subgrouping of trials. Trials in which the
mean length of follow up exceeded two years showed
somewhat larger reductions in combined cardiovas›
cular events (0.76 (0.65 to 0.90) v 0.96 (0.75 to 1.23)
than trials of less than two years’ duration). When we
excluded data from the Oslo diet›heart study, the rate
ratio for combined cardiovascular events for trials with
mean follow up longer than two years was not altered
(0.77; 0.62 to 0.96). Total mortality was not substantially
influenced by mean follow up.
The relation between mean follow up and
cardiovascular events was further explored through
meta›regression. The negative slope (ln (rate ratio) v
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mean follow up time, slope –0.096; –0.190 to –0.002)
suggests fewer cardiovascular events at longer mean
follow up times in the groups with reduced or modified
fat intake.
Trials with participants at high initial cardiovas›
cular risk suggested very similar levels of protection
from combined cardiovascular events (rate ratio 0.84;
0.70 to 0.99) as did trials with participants at low
cardiovascular risk (0.82; 0.56 to 1.20). Neither the
method of dietary modification (by diet advice, advice
plus a supplement, or diet provided) nor the initial
level of intake of dietary fat influenced rate ratios.
Changes in fat intake and blood cholesterol
concentration
We used meta›regression to explore the effects on total
mortality and combined cardiovascular events of chang›
ing the proportion of energy from total fat and of alter›
ing serum cholesterol concentrations. Meta›regressions
also explored the relation between change in pro›
portion of saturated fat, polyunsaturated fat, and
monounsaturated fat on cardiovascular events. These
suggested that total mortality and cardiovascular events
were reduced as energy from fat, and as serum
cholesterol concentrations, fell. Similarly, cardiovascular
Table 1 Outcome data from included trials of diet and health for control/intervention groups
Included trial arm
Person years of
observation Total mortality CVD mortality Combined CVD events Events included in combined CVD events
BDIT pilot studies16 1138/986 3† — — —
Diet and reinfarction (DART)17 1917/1925 113/111 100/101 147/136 CV deaths (including stroke) plus non›fatal MI
Diet and gallstones18 10/11 0 — — —
German fat reduced19 25/26 0 0 0 CV deaths, non›fatal MI, stroke
Glasgow diet in hypertension20 34/33 0 0 0 CV deaths
Glasgow weight loss21 22/24 0 0 0 CV deaths, non›fatal MI, stroke
Kentucky low fat22 56/105 0 0 0 CV deaths, fatal and non›fatal MI, stroke
Kuopio23:
Fat modified (American Heart
Association)
6/20 0 — — —
Fat modified (low fat) 6/20 0 — — —
Fat modified (mono) 6/20 0 — — —
Linoleic enrichment 24 40/34 0 0 0 CV deaths, non›fatal MI, stroke
London corn/olive25:
Corn 22/41 0.5/5 0.5/5 5.5/15 CV deaths, non›fatal MI, angina, stroke
Olive 22/38 0.5/3 0.5/3 5.5/11 CV deaths, non›fatal MI, angina, stroke
London low fat 26 393/374 24/20 20/17 42 / 38 CV deaths, non›fatal MI
Low fat in breast cancer27 171/170 At least 2†
Mastopathy diet28 4/5 0 0 0 CV deaths
Minnesota coronary29 4715/4823 248/269 157/157 129/134 Total MI, sudden death, stroke
MRC soya30 715/751 31/28 25/27 74/62 CV deaths, total MI
Multicentre study on fat reduction
(MSFAT)31
56/59 0 — — —
National diet›heart study32:
Faribault 1st, B 18/52 — 0 0 Total MI, peripheral vascular events
Faribault 1st, C 18/49 — 0 0 Total MI, peripheral vascular events
Faribault 1st, E 18/53 — 0 0 Total MI, peripheral vascular events
Open 1st, B 120/358 — 0 0.3/0 Total MI, peripheral vascular events
Open 1st, C 120/361 — 0 0.3/4 Total MI, peripheral vascular events
Open 1st, X 120/50 — 0 0.3/1 Total MI, peripheral vascular events
Open 2nd, BC 59/112 — 0 1.3/0 Total MI, peripheral vascular events
Open 2nd, F 59/74 — 0 1.3/1 Total MI, peripheral vascular events
Open 2nd, G 59/70 — 0 1.3/0 Total MI, peripheral vascular events
Open 2nd, X 22/22 — 0 0 Total MI, peripheral vascular events
Oslo diet›heart33 885/895 65/48 52/38 91/66 Total MI, sudden death, stroke, angina
Oxford retinopathy34 1160/1160 34† — — —
Sollentuna diet35 19/20 0 0 0 Total MI, CV deaths, stroke
Stanford weight36 42/42 0 0 0 CV deaths
St Thomas’ atherosclerosis regression
(STARS)37
88/91 3/1 3/1 20/8 CV deaths, non›fatal MI, angina, stroke, CABG,
angioplasty
Sydney diet›heart38 1011/939 28/39 — — —
Toronto polyp prevention39 204/198 0 0 0 CV deaths
Turku weight40:
Mixed 21/41 0 0 0 CV deaths, non›fatal MI, angina, stroke, heart failure,
angioplasty, CABG
Vegetarian 21/38 0 0 0 CV deaths, non›fatal MI, angina, stroke, heart failure,
angioplasty, CABG
Veterans administration41 1544/1588 177/174 59/44 122/97 Sudden death, definite MI, definite stroke, angina,
peripheral vascular events
Veterans diet and skin cancer42 125/123 2/1 2/0 2/0 CV deaths
Total, all trials 15096/15806 (30 902) 692/699 (1430) 419/393 (812) 643/573 (1216) —
Total, high risk participants 5053/5054 (10 107) 265/255 (520) 201/192 (393) 385/336 (721) —
CVD=cardiovascular disease, CV=cardiovascular, MI=myocardial infarction, CABG=coronary artery bypass grafting.
*Events counted only once, only major event counted for each participant.
†Deaths occurred but it was not clear in which group.
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events were reduced as each of the fat subfractions
decreased. However, none of these relations were
convincing (none of the slopes were different from zero
at a P < 0.05, see table 2), except for that of monounsatu›
rated fat. Here the slope depended heavily on one
medium sized trial, St Thomas’s atherosclerosis
regression study (STARS),37 and should therefore be
treated with caution.
Discussion
Pooled results of dietary fat trials indicate that
reduction or modification of intake of dietary fat
reduces the incidence of combined cardiovascular
events by 16% (rate ratio 0.84; 95% confidence interval
0.72 to 0.99) and cardiovascular deaths by 9% (0.91;
0.77 to 1.07). No effect was seen on total mortality.
Exclusion of data from the Oslo diet study33 attenu›
ated the effects on cardiovascular events. In this trial
participants in the intervention group were supplied
with oily fish, in addition to dietary advice. Oily fish,
which is rich in omega 3 fatty acids, seems to have
independent beneficial effects,44 so the benefits seen in
this trial may have been due to the fish oils and not to
cholesterol lowering or alterations in other dietary fats.
Duration of trial effect
Subgrouping by length of mean follow up suggests
that virtually all protection from cardiovascular events
occurs in trials of at least two years’ duration. In trials
with mean follow up of two years or less the reduction
in events was only 4%, whereas in trials with longer fol›
low up reductions of up to 24% were seen. This effect
was confirmed in a meta›regression.
The division at two years was chosen after we stud›
ied initial data from the Scandinavian simvastatin sur›
vival study (4S), which assessed the effect of simvastatin
on mortality and morbidity after myocardial infarc›
tion.45 In that study little difference in event rates
between treated and control groups emerged until
after two years. The similar time lag between the effects
of dietary intervention and statins suggests a common
mechanism, perhaps through effects on the scale, type,
and stability of atherosclerotic plaques (rather than
rapid alteration in blood coagulability), but other
mechanisms may also be operating.
It is not clear whether it is the duration of the inter›
vention or the duration of the follow up that
determines whether the intervention is effective.
Sustained change in dietary behaviour, promoted by
long interventions, is probably necessary to achieve
reduction in cardiovascular events, and lengthy follow
up is probably required before pathophysiological
changes that reduce clinical events are observed.
Initial level of cardiovascular risk
Subgrouping suggested no effect of initial level of risk
on outcomes. Both high and low risk groups had a
similar level of risk reduction for combined cardiovas›
cular events. This is in contrast to results of previous
studies,46 though initial levels of risk in studies in this
systematic review were generally high (people in
control group at “low risk” of cardiovascular events suf›
fered 2.57 events per 100 people per year and those at
“high risk” 7.62 events per 100 people per year).
Most of the events in this review occurred in men.
Only two trials with events included women29 42 so it
may not be appropriate to generalise these results to
women.
Type of intervention
Subgrouping by mode of intervention showed no ben›
efit of providing the entire diet compared with dietary
advice or advice and a supplement. This was surprising
as we expected that provision of food would have a
more powerful effect on events than dietary advice
alone.
Changes in blood cholesterol concentration
Meta›regression provided weak evidence that a greater
reduction in serum cholesterol concentrations in the
intervention group compared with the control group
resulted in a slightly greater reduction in cardiovas›
cular events and mortality.
A reduction of over 20% in total serum cholesterol
concentration can result in a 25% fall in mortality from
coronary heart disease.47 Within dietary trials in this
review the mean initial serum cholesterol concentra›
tion was 5.8 mmol/l, with a fall of 0.64 mmol/l (11%).
This degree of reduction is similar to that achieved by
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Fig 2 Estimates of total mortality (95% confidence intervals) from
meta›analysis
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Fig 3 Estimates of cardiovascular mortality (95% confidence
intervals) from meta›analysis
Papers
760 BMJ VOLUME 322 31 MARCH 2001 bmj.com
early fibrates, which show reductions in rates of coron›
ary heart disease only among those at high risk.46 How›
ever, early fibrates seemed to increase mortality from
other causes, and hence any benefit from this reduction
in cholesterol concentration was outweighed by
adverse effects of the drugs themselves. In dietary
modification this degree of cholesterol lowering is
probably of modest overall benefit.
Methodology of the review
In this review we aimed to find trials that modified or
reduced dietary fat intake for at least six months, even
when mortality and morbidity were not reported. We
tried to contact trial authors to ascertain whether it was
known if any deaths or cardiovascular events had
occurred. For this reason, many of the included trials
are small but are included in the hope of augmenting
the data from larger trials and reducing bias. Although
small trials cannot individually hope to achieve useful
data on rare events, in meta›analysis we are increasing
the power of the group of studies by pooling.
We included factorial trials (for example, the diet
and reinfarction trial (DART)17) when it was possible to
separate out the data on the effect of change in dietary
fat from the other interventions (which are randomly
distributed across the fat control and intervention
groups). We excluded multiple risk factor intervention
trials as it is not possible to disaggregate the effects of
change in dietary fat intake from other, potentially
effective interventions such as increasing exercise,
stopping smoking, and change in other dietary
constituents. There is already a systematic review on
this topic.48 We excluded the Lyon heart study49 as
inclusion in our review was decided by the stated
intention of the trial.49 This trial nowhere states the
intention to reduce or modify dietary fat intake and the
major effect on diet was to increase the omega 3 fat
intake. We excluded the Finnish mental hospital study50
as it was not a truly randomised design (a cluster
randomised trial with only two clusters).
Although we amassed 30 902 person years of
observation, 1430 deaths, and 1216 cardiovascular
events, considerable uncertainty exists over the size of
effects and the means by which they were achieved
given the scarcity of trials longer than two years’ dura›
tion. It is unlikely that further resources will now be
forthcoming to perform a large trial of dietary modifi›
cation. Consequently the evidence pooled in this
review contributes all that is available to guide clinical
practice and health policy on dietary manipulation.
However, publication of data on deaths or cardio›
vascular events in the large ongoing trials of dietary fat
lowering with cancer end points would augment
currently available data.
Conclusions
In this review we have tried to separate out whether
changes in individual fatty acid fractions are responsi›
ble for any benefits to health (using the technique of
meta›regression). The answers are not definitive, the
data being too sparse to be convincing. We are left with
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Fig 5 Total mortality and combined cardiovascular events (95% confidence intervals) from
subgroup and sensitivity analyses within meta›analyses
Table 2 Effect of modification of dietary fat intake and serum
cholesterol concentration on mortality and cardiovascular
outcomes, results of meta›regressions performed
Outcome measure and test variable Slope (95% CI)
Mortality*
Total fat 0.15 (−0.009 to 0.039)
Serum cholesterol 0.297 (−0.141 to 0.734)
Cardiovascular events*
Total fat 0.004 (−0.012 to 0.021)
Saturated fat 0.009 (−0.047 to 0.064)
Polyunsaturated fat 0.014 (−0.034 to 0.061)
Monounsaturated fat 0.167 (0.046 to 0.288)
Serum cholesterol 0.296 (−0.094 to 0.687)
*ln (rate ratio).
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a suggestion that less total fat or less of any individual
fatty acid fraction in the diet is beneficial.
The findings on cardiovascular events are broadly
in keeping with benefits that might be expected from
modest lowering of cholesterol concentration and cer›
tainly provide support, at an individual level, for the
central role of dietary fat intake in the causation of
cardiovascular disease.
This study was conducted as a Cochrane systematic review
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The effectiveness of exercise as an intervention in the
management of depression: systematic review and
meta›regression analysis of randomised controlled trials
Debbie A Lawlor, Stephen W Hopker
Abstract
Objective To determine the effectiveness of exercise
as an intervention in the management of depression.
Design Systematic review and meta›regression
analysis of randomised controlled trials obtained from
five electronic databases (Medline, Embase, Sports
Discus, PsycLIT, Cochrane Library) and through
contact with experts in the field, bibliographic
searches, and hand searches of recent copies of
relevant journals.
Main outcome measures Standardised mean
difference in effect size and weighted mean difference
in Beck depression inventory score between exercise
and no treatment and between exercise and cognitive
therapy.
Results All of the 14 studies analysed had important
methodological weaknesses; randomisation was
adequately concealed in only three studies, intention
to treat analysis was undertaken in only two, and
assessment of outcome was blinded in only one. The
participants in most studies were community
volunteers, and diagnosis was determined by their
score on the Beck depression inventory. When
compared with no treatment, exercise reduced
symptoms of depression (standardised mean
difference in effect size –1.1 (95% confidence interval
–1.5 to –0.6); weighted mean difference in Beck
depression inventory –7.3 (–10.0 to –4.6)). The effect
size was significantly greater in those trials with
shorter follow up and in two trials reported only as
conference abstracts. The effect of exercise was similar
to that of cognitive therapy (standardised mean
difference –0.3 (95% confidence interval –0.7 to 0.1)).
Conclusions The effectiveness of exercise in reducing
symptoms of depression cannot be determined
because of a lack of good quality research on clinical
populations with adequate follow up.
Introduction
Depression is a common and important cause of mor›
bidity and mortality worldwide. The effect of exercise
on depression has been the subject of research for sev›
eral decades, and the literature on the subject is grow›
ing.1 In the past decade “exercise on prescription”
schemes have become popular in primary care in the
United Kingdom,2 many of which include depression
as a referral criterion.
Several plausible mechanisms for how exercise
affects depression have been proposed. In the
developed world taking regular exercise is seen as a
virtue; the depressed patient who takes regular exercise
may, as a result, get positive feedback from other
people and an increased sense of self worth. Exercise
may act as a diversion from negative thoughts, and the
mastery of a new skill may be important.3 4 Social con›
tact may be an important mechanism, and physical
activity may have physiological effects such as changes
in endorphin and monoamine concentrations.5 6
This review summarises the evidence from
randomised controlled trials of the effectiveness of
exercise as a treatment for depression.
Methods
Identification of the studies
We searched Medline (1966›99), Embase (1980›99),
Sports Discus (1975›99), PsycLIT (1981›99), the
Cochrane Controlled Trials Register, and the
Cochrane Database of Systematic Reviews using the
terms “exercise,” “physical activity,” “physical fitness,”
“walking,” “jogging,” “running,” “cycling,” “swimming,”
“depression,” “depressive disorder,” and “dysthymia.”
We also examined bibliographies, contacted experts,
and hand searched copies published in the 12 months
to December 1999 of selected journals (for details see
the longer version of this paper on the BMJ ’s website).
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